A

Cambridge, Mass., biotech says it has signed a deal with Swiss drug giant  Roche (ROG) to develop new medicines to combat drug-resistant “superbugs,” three weeks after the World Health Organization said the world is running out of effective antibiotics.

Warp Drive Bio has been working for over a year to identify more than 100 new classes of potential antibiotics, using what it calls “genome mining platform” — including a vast database of genetic material that corresponds to more than 135,000 bacterial strains.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.